Healthcare Jan 26, 2022 10:59 PM (GMT+8) · EqualOcean
Today, Northland announced that important clinical trial projects have achieved phased results. "Recombinant human thymosin for injection", one of the projects raised and invested by the company β The phase IIa clinical trial for the treatment of indications of ischemia-reperfusion injury in acute myocardial infarction has completed the enrollment, follow-up and data statistical analysis, and obtained the preliminary research results. The company said that as the first study to observe patients with target indications, this project has achieved the purpose of preliminary exploration of drug administration safety, effective dose range and selection of evaluation indicators, which provides a basis for follow-up research. At present, the company is actively preparing to carry out follow-up phase IIB clinical trials.